SCHEMBL20969671

SCHEMBL20969671

COc1ccc(CCN(c2nc3cccc(F)c3s2)C(C)c2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KARS1 Q15046 1/20 0.50
TAS2R14 Q9NYV8 4/20 0.41
LPAR1 Q92633 7/20 0.41
LPAR5 Q9H1C0 7/20 0.41
TRPM8 Q7Z2W7 1/20 0.41
FFAR1 O14842 1/20 0.40
PTGER4 P35408 1/20 0.39
MMP10 P09238 1/20 0.37
MMP8 P22894 1/20 0.37
MMP13 P45452 1/20 0.37
NPC1 O15118 1/20 0.36
POLB P06746 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
GAA P10253 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20969634 0.90 KARS1 (0.51) KARS1TAS2R14LPAR1LPAR5TRPM8
SCHEMBL20969620 0.90 KARS1 (0.49) KARS1TAS2R14LPAR1LPAR5TRPM8
SCHEMBL20969631 0.90 KARS1 (0.50) KARS1TAS2R14LPAR1LPAR5TRPM8
SCHEMBL20969619 0.90 KARS1 (0.46) KARS1TAS2R14LPAR1LPAR5TRPM8
SCHEMBL20969668 0.89 PTGER4 (0.40) KARS1TAS2R14LPAR1LPAR5TRPM8
SCHEMBL20969637 0.89 KARS1 (0.48) KARS1TAS2R14LPAR1LPAR5TRPM8
SCHEMBL20969728 0.89 KARS1 (0.38) KARS1TAS2R14LPAR1LPAR5TRPM8
SCHEMBL20969571 0.89 KARS1 (0.46) KARS1TAS2R14LPAR1LPAR5TRPM8
SCHEMBL20969741 0.88 KARS1 (0.38) KARS1TAS2R14LPAR1LPAR5TRPM8
SCHEMBL20969659 0.87 KARS1 (0.46) KARS1TAS2R14LPAR1LPAR5TRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3483149-B1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME YUHAN CORP (KR) 2021-01-13 EP claimed
US-10383859-B2 Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same YUHAN CORPORATION (KR) 2019-08-20 US claimed
US-20190142809-A1 Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same YUHAN CORPORATION (KR) 2019-05-16 US claimed
EP-3483149-A1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Yuhan Corporation (KR) 2019-05-15 EP claimed
EP-3483149-B1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME YUHAN CORP (KR) 2021-01-13 EP disclosed
US-10383859-B2 Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same YUHAN CORPORATION (KR) 2019-08-20 US disclosed
US-20190142809-A1 Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same YUHAN CORPORATION (KR) 2019-05-16 US disclosed
EP-3483149-A1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Yuhan Corporation (KR) 2019-05-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190142809-A1 Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same ILK, SBDS, BDKRB1 KARS1 6/4885TAS2R14 1971/4885LPAR1 567/4885
US-10383859-B2 Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same ILK, SBDS, BDKRB1 KARS1 6/4885TAS2R14 1971/4885LPAR1 567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.